European Parliament 30 November 2012, Written question E-010946/12 Willy Meyer (GUE/NGL) to the Commission. Lack of safety in drug authorisation procedures: the case of Reboxetine

Question for written answer E-010946/12 to the Commission Willy Meyer (GUE/NGL) (30 November 2012) Subject: Lack of safety in drug authorisation procedures: the case of Reboxetine In 2010 a group of German researchers discovered that Reboxetine, the active principal of a drug used to treat clinical depression, had no effect at all on health.